New therapy strategies for primary sclerosing cholangitis indicate initial success

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid (norUrso). A multi-centric phase II study with 45 involved centers from all across Europe demonstrated that when norUrso was administered to 161 patients for the first time “there were significant improvements in liver function test results in all tested dosing” according one researcher.